Abstract 566P
Background
The CinClare phase III study (NCT02605265) demonstrated that the addition of irinotecan to capecitabine in combination with radiotherapy significantly increased the pathologic complete response(pCR) rate in locally advanced rectal cancer (LARC). However, it was not well tolerated among some patients, who failed to complete their planned weekly irinotecan chemotherapy. This study is a post-hoc analysis of the CinClare study designed to assess the impact of irinotecan chemotherapy completion in preoperative chemoradiotherapy on efficacy, toxicity, and long-term survival.
Methods
Patients were categorized into three groups based on the cycles of weekly irinotecan they actually received in the CinClare study. Group A received only capecitabine, while Group B and C actually received 1-3 or 4-5 cycles of weekly irinotecan during the course of chemoradiotherapy, respectively. Tumor response, toxicity, and long-term survival were compared among the three groups.
Results
A total of 356 patients were included in the analysis. The pCR rates were 17.4%, 20.8%, and 38.4% in Groups A, B, and C, respectively (P < 0.001). Grade 3-4 adverse events were 6.2%,52.8%,32.0% respectively. The 5-year DFS and OS rates in Groups A, B, and C were 70.6% vs. 76.9% vs. 78.1% and 76.1% vs. 80.0% vs. 84.2%, respectively.
Conclusions
The administration of 4-5 cycles of weekly irinotecan in preoperative chemoradiotherapy was significantly associated with better tumor response and showed a trend toward beneficial DFS and OS in patients with LARC.
Clinical trial identification
NCT02605265.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16